Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 3/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787407 | 0.86 | MGAM (0.64) | MGAMNAPRTHCAR2ALDH1A1APP | |
| Isoquinoline SCHEMBL28152444 | 0.84 | MGAM (0.77) | MGAMALDH1A1PSMD14MRGPRX4NPC1 | |
| SCHEMBL721917 | 0.84 | HPGDS (0.55) | MGAMHPGDSALDH1A1PSMD14LRRK2 | |
| SCHEMBL35212113 | 0.82 | HPGDS (0.44) | MGAMHPGDSALDH1A1LRRK2NPC1 | |
| SCHEMBL28946126 | 0.80 | ALOX15 (0.54) | HPGDSALDH1A1GAAPSMD14KDM4E | |
| SCHEMBL4900459 | 0.80 | HPGDS (0.55) | MGAMHPGDSALDH1A1LRRK2NPC1 | |
| SCHEMBL11411063 | 0.79 | MAPK10 (0.58) | MGAMCSNK2A2CSNK2BMRGPRX4HIPK2 | |
| SCHEMBL69368 | 0.78 | MGAM (0.68) | MGAMHPGDSNAPRTALDH1A1GAA | |
| SCHEMBL28048 | 0.78 | MGAM (1.00) | MGAMHPGDSALDH1A1PSMD14NPC1 | |
| SCHEMBL29362407 | 0.78 | MGAM (1.00) | MGAMHPGDSALDH1A1PSMD14NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021011724-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| CN-107922348-A | Bicyclic heterocyclic amide derivatives | 大日本住友制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
| EP-3027597-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-06-08 | — | — | EP | disclosed |
| CN-105473568-A | 1, 7-naphthyridine derivatives | HOFFMANN LA ROCHE | 2016-04-06 | — | — | CN | disclosed |
| WO-2015014768-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-05 | — | — | WO | disclosed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| WO-2010112826-A2 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | MGAM 3626/4885HPGDS 291/4885NAPRT 3261/4885 |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | MGAM 2972/4885HPGDS 929/4885NAPRT 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.